SRR12202490
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.380
- PANCREAS_BETA_CELLS+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- SPERMATOGENESIS+0.300
- MYOGENESIS+0.220
- KRAS_SIGNALING_UP+0.170
- COAGULATION+0.150
- APICAL_SURFACE+0.140
- ANGIOGENESIS+0.130
- ALLOGRAFT_REJECTION+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.460
- OXIDATIVE_PHOSPHORYLATION-0.450
- TGF_BETA_SIGNALING-0.450
- DNA_REPAIR-0.440
- MYC_TARGETS_V1-0.410
- MYC_TARGETS_V2-0.400
- PROTEIN_SECRETION-0.400
- ADIPOGENESIS-0.360
- TNFA_SIGNALING_VIA_NFKB-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516036 | — | — | 0.909 |
| 2 | SRR1316624 | GTEX | — | 0.895 |
| 3 | R415 | — | — | 0.891 |
| 4 | SRR1451964 | GTEX | — | 0.886 |
| 5 | SRR1382956 | GTEX | — | 0.884 |
| 6 | SRR1336006 | GTEX | — | 0.880 |
| 7 | MNG1137 | — | — | 0.880 |
| 8 | SRR1500405 | GTEX | — | 0.879 |
| 9 | SRR13311184 | — | — | 0.879 |
| 10 | BS_0X9EGHY2 | low-grade glioma | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.380 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |